What We Do
Pipeline
Welcome to the pipeline page of Bioron, showcasing our latest efforts in advancing research-driven solutions in neurological science. Our commitment lies in addressing unmet medical needs through scientific discovery and clinical excellence.
Below, we detail our current portfolio of investigational programs in various stages of clinical and translational research.
BRP-180
Bupropion Novel Formulation
• *Indication:* Narcolepsy
• *Description:* This innovative formulation of Bupropion, featuring a biphasic modified release profile, is designed to effectively manage narcolepsy symptoms. Granted orphan drug designation, it underscores our commitment to addressing rare diseases.
• *Development Stage:* Phase 2b (In Progress)
• *Regulatory Pathway:* FDA 505(b)(2)
BRP-199
Oral Cannabidiol Novel Formulation
• *Indication:* Rett Syndrome
• *Description:* Our novel oral formulation of cannabidiol aims to offer a significant therapeutic option for Rett Syndrome, a rare neurodevelopmental disorder. We are dedicated to enhancing the quality of life for these patients.
• *Development Stage:* Pivotal Phase 2 (Under Development)
• *Regulatory Pathway:* FDA 505(b)(2)
BRP-343
Esketamine Novel Formulation
• *Indication:* Treatment-Resistant Depression (TRD)
• *Description:* A novel delivery method of Esketamine via a prefilled subcutaneous syringe, targeting TRD. This approach seeks to provide rapid and effective relief for patients who have not responded to traditional treatments.
• *Development Stage:* Phase 2b
• *Regulatory Pathway:* FDA 505(b)(2)
BRP-412
CBD and Esketamine FDC
• *Indication:* Major Depressive Disorder (MDD)
• *Description:* A fixed-dose combination of CBD and Esketamine developed for the treatment of Major Depressive Disorder. This innovative approach leverages the synergistic effects of both compounds to offer a potentially more effective treatment option for MDD patients.
• *Development Stage:* Phase 2b Study
• *Regulatory Pathway:* FDA 505(b)(2)
